Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96
Conditions
Liver Cancer - Pancreatic Adenocarcinoma
Conditions: official terms
Adenocarcinoma
Study Type
Interventional
Study Phase
Phase 1/Phase 2
Study Design
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: autologous gp96 vaccination
Type: Biological
Overall Status
Recruiting
Summary
To evaluate the safety and effectiveness of autologous gp96 treatment of liver cancer and Pancreatic Adenocarcinoma
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 75 Years
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

1. Able to read and understand the informed consent document; must sign the informed consent;

2. Aged 18 to 75 years old , sex is not limited;

3. Pancreatic cancer or primary liver cancer,must have undergone radical resection;

4. Availability of at least 0.5 g tumor sample;

5. Receiving the first gp96 autologous immunotherapy within 8 weeks of postoperation;

6. Patients could not have received previous chemotherapy, radiation, or immunotherapy before 4 weeks of gp96 treatment;

7. ECOG ≤1;life expectancy of at least 12 weeks

8. Adequate bone marrow function including the absence of lymphopenia (ANC > 1,500/ mm3; Hemoglobin > 10g/dL ; platelet count >100,000/mm3), adequate liver function (serum glutamic oxaloacetic transaminase/ aspartate aminotransferase [AST], alanine amino transferase [ALT] <2.5 times institutional upper limit of normals [IULNs] and bilirubin (total) <1.5 times IULN), and adequate renal function (BUN and creatinine <1.5 times IULNs); 9. Agree to Surgical indications of Heart & lung and without the coagulation system disease;

10.Negative pregnancy test for female patients of childbearing potential; 11.Agree to use contraception or abstain from sexual activity from the time of consent through 3 month after the end of study drug administration.

Exclusion Criteria:

1. Unable to get the informed consent ;

2. Patient not suitable for radical resection;

3. Patients with active liver disease;

4. Did not get enough tumor tissue ;

5. Progression prior to vaccination as determined by the Principal Investigator;

6. Rreceiving other anti-cancer therapy at the same time;

7. Patient with allergic constitution;

8. Unstable or severe intercurrent medical conditions;

9. Current diagnosis of Human Immunodeficiency Virus and Patients with active uncontrolled infection;

10. Patients with any systemic disease needed to be treated with immunosuppressant or Corticosteroids;

11. Any other cilical trials within 30 days pre-vaccination;

12. Female patients who are pregnant or breastfeeding.
Location
Cancer Insititute and Hospital,Chinese Academy of Medical Sciences
Beijing, China
Status: Recruiting
Start Date
March 2012
Completion Date
July 2016
Sponsors
Cure&Sure Biotech Co., LTD
Source
Cure&Sure Biotech Co., LTD
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page